Quantgene Now Has an At-Home Saliva Test to Help Detect Cancer Risk

Quantgene Now Has an At-Home Saliva Test to Help Detect Cancer Risk

Biotech startup Quantgene released an at-home saliva to test for cancer risk, hoping to compete with other genetics companies as it develops even more precise ways to detect the disease.

The Santa Monica-based company, which aims to extend human life by a decade, released an at-home DNA sequencing test to the public last month to help customers understand hereditary factors that may lead to a cancer diagnosis.

This is one part of Quantgene's four-pronged cancer test, known as Serenity, that uses family history, genetics counselors, a blood test and exome sequencing to scan large chunks of DNA. The company ultimately aims to catch cancer in its first and second stages of development, before it becomes deadly.

"We hope to unlock a new era in medicine in which trained physicians can detect multiple cancers at early stages in the blood with single molecule precision," Quantgene CEO and founder Jo Bhadki said in an announcement.

People can request an at-home saliva test from Quantgene's website and have a genetic counselor interpret its results. According to the company, the cost is less than $1,000 and the test also looks at the risk for other diseases.

The company is also working on a blood test that screens for multiple cancers using a single draw. Quantgene has been working on this early-detection cancer technology for the last five years and is accepting patients via waitlist.

Earlier this week, announced it secured $6 million in funding led by Vikor Scientific, a life science company based out of South Carolina. As part of the investment, Vikor will take a stake in the company and help market Quantgene's services to its database of medical providers, establishing a presence on the East Coast.

The idea for Quantgene began at an U.C. Berkley lab. The company has raised $13 million from two previous rounds of fundraising.

The company aims to establish Los Angeles and South Carolina, where Vikor is headquartered, as "leading centers in genomics-based medical innovation."

Editor's note: This post has been updated to reflect when the saliva-test was released, correct the investment figures in funding rounds and clarify U.C. Berkeley's role in the company's development.

Subscribe to our newsletter to catch every headline.

Image courtesy of Shutterstock

The age of the creator is upon us.

After years of gaining momentum, the creator economy has gone mainstream. Payment processing platform Stripe estimates the number of individuals who now see themselves as full-time “creators”—those who use online tools to sell digital content—grew 48% in 2021, while earnings across the industry are expected to soon eclipse $10 billion.

Read more Show less
Jolene Latimer
Jolene Latimer has her Master of Arts in specialized journalism and writes about sports, entertainment and personal finance.

It started as a real estate company for startups. Today, Plug and Play operates what it calls an “innovation platform” that offers young companies office space, an accelerator program and — in some cases — invests in them.

On this episode of LA Venture, Plug and Play's CEO and founder Saeed Amidi talks about how he evolved the company into an accelerator and investment firm, and how he uses his platform to introduce many of the world’s largest corporations to startups that are re-envisioning their industries.

Read more Show less
Minnie Ingersoll
Minnie Ingersoll is a partner at TenOneTen and host of the LA Venture podcast. Prior to TenOneTen, Minnie was the COO and co-founder of $100M+ Shift.com, an online marketplace for used cars. Minnie started her career as an early product manager at Google. Minnie studied Computer Science at Stanford and has an MBA from HBS. She recently moved back to L.A. after 20+ years in the Bay Area and is excited to be a part of the growing tech ecosystem of Southern California. In her space time, Minnie surfs baby waves and raises baby people.